NDAINHALATIONPOWDER
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREO ELLIPTA is a twice-daily inhaled combination powder containing fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) approved in 2013. It treats asthma and chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving bronchial tone. The dual mechanism provides sustained symptom control and airway protection in obstructive respiratory diseases.
$1.4BPart D
PeakStable
4.4 years to LOEBREO ELLIPTA is in peak commercial phase with substantial Part D utilization, indicating a large and established commercial infrastructure with mature team structures and stable revenue streams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma
Started Apr 2026
0Respiratory
Why This Matters for Your Career
Worked on BREO ELLIPTA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.